Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 CAD | -50.00% | -.--% | -50.00% |
2023 | Molecule Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 | CI |
2023 | Molecule Holdings Inc. Announces Change of Chief Financial Officer | CI |
Valuation
Fiscal Period: Oktober | 2020 | 2021 | 2022 |
---|---|---|---|
Capitalization 1 | 7.244 | 5.723 | 4.4 |
Enterprise Value (EV) 1 | 6.978 | 8.96 | 9.513 |
P/E ratio | -1.93 x | -1.3 x | -0.96 x |
Yield | - | - | - |
Capitalization / Revenue | - | 12,570,392 x | 2,235,414 x |
EV / Revenue | - | 19,680,785 x | 4,832,667 x |
EV / EBITDA | -3.92 x | -3.12 x | -2.87 x |
EV / FCF | -10.6 x | -4.29 x | -50.4 x |
FCF Yield | -9.4% | -23.3% | -1.98% |
Price to Book | 2.13 x | 8.96 x | -1.19 x |
Nbr of stocks (in thousands) | 85,229 | 95,379 | 97,782 |
Reference price 2 | 0.0850 | 0.0600 | 0.0450 |
Announcement Date | 21-02-19 | 22-02-28 | 23-05-15 |
Income Statement Evolution (Annual data)
Fiscal Period: Oktober | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Net sales | - | - | 0.4553 | 1.968 |
EBITDA 1 | -1.069 | -1.782 | -2.875 | -3.31 |
EBIT 1 | -1.097 | -1.83 | -3.394 | -3.914 |
Operating Margin | - | - | -745.48% | -198.86% |
Earnings before Tax (EBT) 1 | -1.091 | -3.327 | -4.227 | -4.544 |
Net income 1 | -1.091 | -3.327 | -4.227 | -4.544 |
Net margin | - | - | -928.56% | -230.84% |
EPS 2 | -0.0234 | -0.0439 | -0.0460 | -0.0468 |
Free Cash Flow 1 | -1.964 | -0.6561 | -2.091 | -0.1886 |
FCF margin | - | - | -459.26% | -9.58% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 20-09-17 | 21-02-19 | 22-02-28 | 23-05-15 |
Balance Sheet Analysis
Fiscal Period: Ottobre | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Net Debt 1 | - | - | 3.24 | 5.11 |
Net Cash position 1 | 2.07 | 0.27 | - | - |
Leverage (Debt/EBITDA) | - | - | -1.126 x | -1.544 x |
Free Cash Flow 1 | -1.96 | -0.66 | -2.09 | -0.19 |
ROE (net income / shareholders' equity) | -50.5% | -85.8% | -207% | 297% |
ROA (Net income/ Total Assets) | -26.8% | -21.8% | -37.2% | -49.6% |
Assets 1 | 4.068 | 15.27 | 11.36 | 9.164 |
Book Value Per Share 2 | 0.0600 | 0.0400 | 0.0100 | -0.0400 |
Cash Flow per Share 2 | 0.0300 | 0.0100 | 0.0100 | 0 |
Capex 1 | 1.59 | 1.9 | 0.08 | 0.03 |
Capex / Sales | - | - | 16.88% | 1.68% |
Announcement Date | 20-09-17 | 21-02-19 | 22-02-28 | 23-05-15 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-50.00% | 358K | |
+6.79% | 271B | |
+2.81% | 46.43B | |
+15.35% | 22.21B | |
+46.70% | 18.64B | |
-6.66% | 17.21B | |
+23.68% | 11.3B | |
+2.80% | 11.1B | |
+5.67% | 9.2B | |
+44.91% | 6.01B |
- Stock Market
- Equities
- MLCL Stock
- Financials Molecule Holdings Inc.